NYSE:UNH

UnitedHealth Group Inc (UNH)

397.14
-3.80 (0.95%)
as of Sep 4, 2026, 8:00:00 pm Market Open.
289 watching
0
Investor Insights
star iconSep 6, 2026, 12:00 am

This summary was created by AI, based on 32 opinions in the last 12 months.

UnitedHealth Group Inc (UNH) has seen mixed reviews from experts, with opinions fluctuating based on recent performance and external regulatory pressures. Some analysts express cautious optimism, noting that the company's fundamentals are improving and that it has potential for growth amid a challenging healthcare landscape. The return of the former CEO has sparked hope for effective cost management and operational improvements, potentially aiding in regaining investor confidence. However, there are concerns over high medical costs, regulatory scrutiny, and a turbulent political environment that could affect profitability. While some see opportunities for recovery and price appreciation, others highlight the risks associated with its reliance on Medicare funding and regulatory changes.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
CVS, CVS
DON'T BUY

Has plunged 22% since reporting last Thursday and dragged the sector down. What in the world happened? They missed top and bottom lines, but worse they cut their full-year earnings forecast by 12%, citing high medical costs in its Medicare plans. The health profiles of many patients has been inaccurate., especially in their managed care business. Their medical care ratio was 84.8% in Q1 2025, but they guided full year at 87.5%. However, UNH's peers are faring better. UNH is having execution problems and is no longer best of breed.

BUY ON WEAKNESS

Down today, so an opportunity. The largest health insurer can do anything it wants under this presidency.

BUY

It reports Thursday. Not too high of a PE and not overly loved and purely domestic. It has pricing power.

BUY ON WEAKNESS

Is up 10% in the past month. Don't chase a red hot stock, but let it come in a bit (lower). Every time this spikes, it goes down. It's best of breed.

BUY

Near term, this can't trade at prior multiples given volatility. Anything healthcare is uncertain. He still believes in the $600 price target. Great management. They have growth.

HOLD

Leader in the space. Trades at 16x forward PE, 11% growth. Last 5 years, earnings have growth 12% a year. 200-day MA trending higher, but price is a bit below that, so technical signals are neutral. Integrated model strong. Pricing power. Down 24% from recent highs on regulatory concerns, overdone.

BUY ON WEAKNESS

Is down 20% in 6 months and trades at 6.5x EBITA vs. 12x historically, strong managers, $20 billion free cash flow and new share buybacks.

PARTIAL SELL

The DOJ is going after them for Medicare payments. Is taking some risk off the table.

BUY ON WEAKNESS
Enter now on weakness?

Yes. It was a top pick of his last spring. He doesn't think there will be much negative impact from Washington investigating their billing practices, though there remains headline risk. Fundamentals are improving, though they are paying out more for medical costs, which he hopes will normalize. It's trading below the market PE, when usually it trades above.

TOP PICK

It is integral to the systematic delivery of health care across the U.S. and is a leader in well vertically integrated companies. There are some headwinds which he thinks will dissipate. He likes the longer term prospects and is seeing the development of per capita growth.
Buy 29  Hold 1  Sell 0

(Analysts’ price target is $633.30)
BUY
Value trap or buying opportunity?

He bought some yesterday. Didn't change guidance. Q4 profitability was OK, though revenue was a bit light. Health insurance in US will continue to grow, it's a leader. Core holding for him. Great distribution system, so cost is less than peers. Trump administration will not nationalize healthcare.

PAST TOP PICK
(A Top Pick Mar 17/23, Up 18%)

Well run and uses AI a lot. It's an easy punching bag in the US for critics of the healthcare system. Health is always a political hot knife, but HC is the biggest employer in the US. Some disagree, but it's not in their interest to screw customers (by denying claims). He has been this all the way down.

BUY

Healthcare stocks are no longer struggling with the post-Covid hangover, better earnings recently, and good news about Medicare this evening $21 billion payment boost). He expects a good report.

TOP PICK

Low beta, more conservative name. Very significant scale. Far ahead of peers with strong alignment of medical insurance, pharmacy benefits, and healthcare services. Aging demographics are key drivers of demand. Shares are 19% off their highs, an opportunity. 18x PE for 11% growth. Yield is 1.7%.

(Analysts’ price target is $641.46)
TOP PICK

Most diversified managed health care company (own clinics, software & insurance). Recent assassination of CEO not a major concern in terms of outlook for the business (although was a tragedy). Ability to raise prices very strong, with excellent margins on products. Will continue to buy shares. 

Showing 61 to 75 of 291 entries